A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases

Inclusion Criteria: * Male or female adults aged ≥ 19 to ≤ 75 years \[Parts 1 and 2 only\] * Diagnosis of CSU \[Part 2 only\] * Experience of inadequately uncontrolled CSU despite use of omalizumab \[Part 3 only\] * Diagnosis of chronic inducible urticaria (cold urticaria) Exclusion Criteria: * History of malignancy within 5 years from screening * Aspartate transaminase (AST) or alanine transaminase (ALT) level \> 2 X the upper limit of normal \[Parts 1 and 2 only\] * Chronic urticaria with clear etiology other than CSU \[Part 3 only\] * Chronic urticaria other than studied chronic inducible urticaria (cold urticaria) The above information is not intended to contain all considerations relevant to a patient potential participation in a clinical trial.